Tegaserod
Brand names: Zelnorm · Active ingredient: Tegaserod
In short: ZELNORM is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C). Limitations of Use The safety and effectiveness of ZELNORM in men with IBS-C have not been established .
What is Tegaserod used for?
ZELNORM is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).
Limitations of Use
The safety and effectiveness of ZELNORM in men with IBS-C have not been established .
Tegaserod dosage
The recommended dosage of ZELNORM in adult women less than 65 years of age is 6 mg taken twice daily orally at least 30 minutes before meals . Discontinue ZELNORM in patients who have not had adequate control of symptoms after 4 to 6 weeks of treatment.
How to take Tegaserod — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Cardiovascular Ischemic Events, Including MACE
Inform patients that stroke, myocardial infarction, and cardiovascular death have been reported in adults taking ZELNORM who had an increased risk of developing an adverse cardiovascular event based on their medical history. Advise patients to promptly seek medical attention if they develop symptoms of an MI, stroke, TIA, or angina. Also, advise patients to immediately inform their healthcare provider if they develop clinical or other evidence of cardiovascular ischemic heart disease (e.g., coronary artery disease) or other changes in their health status that could increase cardiovascular risk (e.g., smoking, hypertension, hyperlipidemia, diabetes mellitus, obesity) while taking ZELNORM .
Ischemic Colitis
Advise patients to stop taking ZELNORM and seek medical attention if they develop symptoms of ischemic colitis, such as rectal bleeding, bloody diarrhea or new or worsening abdominal pain . …
Warnings & precautions
Do not take this medicine if: ZELNORM is contraindicated in patients with:
A history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina
A history of ischemic colitis or other forms of intestinal ischemia
Severe renal impairment (eGFR< 15 mL/min/1.73 m2) or end-stage renal disease
Moderate and severe hepatic impairment (Child-Pugh B or C)
A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions
Hypersensitivity to tegaserod
Stroke, MI, and cardiovascular death (major adverse cardiovascular events [MACE]) have been reported in adults taking ZELNORM who had an increased risk of developing an adverse cardiovascular event based on their medical history .
ZELNORM is contraindicated in patients with a history of MI, stroke, TIA, or angina . Assess female patients less than 65 years of age for a history of cardiovascular disease and cardiovascular risk factors prior to treatment with ZELNORM . The potential risks of treatment must be balanced with expectations in improvements in symptoms of IBS-C.
Discontinue ZELNORM in patients who experience an MI, stroke, TIA, or angina . Evaluate the risks and benefits of continued use of ZELNORM in patients who develop clinical or other evidence of cardiovascular ischemic heart disease (e.g., coronary artery disease) and/or experience changes in health status that could increase cardiovascular risk during treatment with ZELNORM.
Ischemic colitis and other forms of intestinal ischemia have been reported postmarketing in patients receiving ZELNORM . In some cases, hospitalization was required. Discontinue ZELNORM in patients who develop symptoms of ischemic colitis, such as rectal bleeding, bloody diarrhea, or new or worsening abdominal pain. …
Tegaserod side effects
The following adverse reactions are discussed in more detail elsewhere in the labeling:
Cardiovascular Ischemic Events, including MACE
Ischemic Colitis
Volume Depletion Associated with Diarrhea
Suicidal Ideation and Behavior
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Common Adverse Reactions
In three clinical trials 2,343 female patients less than 65 years of age with IBS-C received ZELNORM 6 mg twice daily or placebo. The majority of patients were Caucasian. Table 1 provides the incidence of common adverse reactions reported in >2% of IBS-C patients in the ZELNORM treatment group and at an incidence that was greater than in the placebo group.
Adverse Reactions | ZELNORM6 mg twice daily[N = 1,184]% | Placebo
[N = 1,159]%
Headache | 14 | 10
Abdominal Painb | 11 | 10
Nausea | 8 | 7
Diarrhea | 8 | 3
Flatulence | 6 | 5
Dyspepsia | 4 | 3
Dizziness | 4 | 3
a Reported in >2% of ZELNORM-treated patients and at an incidence greater than placebo
b Includes abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort, abdominal tenderness, epigastric pain or discomfort
Diarrhea
The majority (84%) of the ZELNORM patients reporting diarrhea had a single episode. In most cases, diarrhea occurred within the first week of treatment. …
About this medicine
ZELNORM oral tablets contain tegaserod, a serotonin-4 (5-HT4) receptor agonist, as the hydrogen maleate salt. As the maleate salt, tegaserod is chemically designated as 3-(5-methoxy-1H-indol-3-ylmethylene)-N-pentylcarbazimidamide hydrogen maleate. Its empirical formula is C16H23N5O•C4H4O4. The molecular weight is 417.47 and the structural formula is:
Tegaserod as the maleate salt is a white to off-white crystalline powder and is slightly soluble in ethanol and very slightly soluble in water. Each ZELNORM tablet contains 6 mg of tegaserod (equivalent to 8.31 mg of tegaserod maleate) and the following inactive ingredients: colloidal silicon dioxide, crospovidone, glyceryl behenate, hypromellose, and lactose monohydrate.
How it works: Tegaserod is an agonist of serotonin type-4 (5-HT4) receptors that stimulates the peristaltic reflex and intestinal secretion, inhibits visceral sensitivity, enhances basal motor activity, and normalizes impaired motility throughout the gastrointestinal tract. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6a44eefe-fbe8-431c-a418-2571b26aa42e. Read the full official label on DailyMed.
Related medicines
Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate